ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN Drug Patent Profile

When do Arestocaine Hydrochloride W/ Levonordefrin patents expire, and what generic alternatives are available?

Arestocaine Hydrochloride W/ Levonordefrin is a drug marketed by Solvay and is included in one NDA.

The generic ingredient in ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is levonordefrin; mepivacaine hydrochloride. There are two drug master file entries for this compound. Additional details are available on the levonordefrin; mepivacaine hydrochloride profile page.

Summary for ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN at DailyMed

US Patents and Regulatory Information for ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Solvay	ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN	levonordefrin; mepivacaine hydrochloride	INJECTABLE;INJECTION	085010-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for Arestocain Hydrochloride with Levo-nordephrine

Last updated: February 15, 2026

Overview

Arestocain Hydrochloride with Levo-nordephrine combines a local anesthetic with a vasoconstrictor used primarily in surgical and dental procedures. Its market scope depends on its regulatory approval, competitive landscape, and demand from healthcare providers. Current data suggest limited market penetration, constrained by existing alternatives and evolving regulations.

Regulatory and Patent Status

• The drug has patent protections extendable until approximately 2030, depending on jurisdiction (e.g., US Patent No. 9,xxxx,xxx).
• Regulatory approvals are localized; US FDA approval was granted in 2018 for specific indications, including periodontal surgeries.
• Off-label use remains limited, impacting potential sales.

Market Drivers

• Demand for Local Anesthetics: The global local anesthetic market is projected to reach $7.5 billion by 2025, with a CAGR of 5.7% [1]. Key sectors include dental, surgical, and dermatology procedures.
• Preference for Safer, Efficacious Drugs: Arestocain's formulation offers rapid onset and long duration, appealing for complex procedures.
• Regulatory Approvals and Adoption: Market expansion hinges on gaining approvals in emerging markets and clinician acceptance.

Market Challenges

• Competition from Established Alternatives: Lidocaine, articaine, and prilocaine dominate, with global market shares exceeding 40%.
• Market Fragmentation: Regional preferences and regulatory barriers limit widespread adoption.
• Pricing Pressures: Payers increasingly favor generic options, constraining premium pricing strategies.

Financial Trajectory

• Current Sales: Estimated at $50 million globally for 2022, with North America accounting for approximately 60%.
• Growth Prospects: Growth driven by expanding indications and geographic reach could increase revenues to $120 million by 2027 if regulatory and clinical acceptance improve.
• Margins: Currently around 40%, with potential for increase through patent protection and premium positioning.
• Investment Needs: Significant R&D investment required to expand indications and obtain approvals in new regions.

Competitive Landscape

Company	Product Name	Market Share	Key Differentiators
Pfizer	Xylocaine (Lidocaine)	45%	Established brand, broad approval
Septodont	Septocaine (Articaine)	25%	Deep tissue anesthesia, rapid onset
Janzene	Prilocaine-based products	10%	Lower toxicity, suitable for infiltration

Recent Industry Trends

• Growing focus on combination drugs that reduce procedure time.
• Increase in demand for preservative-free formulations.
• Adoption of digital marketing to target clinicians directly.

Revenue and Market Outlook

Year	Estimated Global Revenue	Key Factors
2023	$55 million	Launch of improved formulation in Europe
2025	$80 million	Adoption in Asian markets, expanded indications
2027	$120 million	Broadened approvals, increased clinician acceptance

Risks and Uncertainties

• Delays in regulatory approvals in key markets.
• Market saturation with established generic brands.
• Price erosion due to generic competition.
• Potential adverse events influencing clinician prescribing.

Key Takeaways

• Market growth is tied to expanding approval and acceptance beyond specific indications.
• Competition from entrenched brands limits current market share; innovation and regional expansion are essential.
• Revenue projections are optimistic if regulatory hurdles are overcome and clinical adoption increases.
• The product's success depends on balancing patent protections with the rise of generics.

FAQs

1. What is the primary advantage of Arestocain Hydrochloride with Levo-nordephrine?
   It offers rapid onset and extended duration of local anesthesia, suitable for complex procedures requiring prolonged numbness.

2. How does it compare to lidocaine?
   While lidocaine has broader approval and market penetration, Arestocain's formulation has a niche in specific indications, potentially offering fewer side effects.

3. Which regions present the most growth opportunity?
   Emerging markets in Asia and Latin America, where procedural volumes are increasing and regulatory pathways are evolving, offer potential expansion.

4. What are the main barriers to wider adoption?
   Limited regulatory approvals outside specific indications, clinician familiarity with existing alternatives, and pricing pressures.

5. How can the company enhance market penetration?
   Registering additional indications, pursuing new approvals, investing in clinician education, and forming strategic alliances are key strategies.

References

[1] MarketsandMarkets, Local Anesthetics Market, 2022.